# BPC-157: Cytoprotection and Tissue-Repair Research, Read From the Record

> BPC-157 is a 15-amino-acid gastric pentadecapeptide studied for cytoprotection and tissue repair. A cited readout of what the research shows, where human data stop, and how access stands.

A field-station readout of the literature: the angiogenesis mechanism, the per-kilogram dose record, the three small human pilots that exist, and how compounded access actually stands. Every quantitative claim is cited.

## What the BPC-157 record shows

BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found in human gastric juice. Its authors call it a stable gastric pentadecapeptide, and across three decades of preclinical work it has produced one consistent theme: cytoprotection — the protection and repair of tissue. The strongest single mechanism in the literature is angiogenesis, the formation of new blood vessels, driven through the VEGFR2-Akt-eNOS pathway [3].

The sequence is `Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val`, molecular formula `C62H98N16O22`, molecular weight `1419.53 Da`, `CAS 137525-51-0`. BPC-157 is not an endogenous circulating hormone; it is a synthetic stable fragment.

The evidence is overwhelmingly animal. As of 2025 reviews, only three small human pilot studies exist [10][11][14], and rigorous large-scale controlled trials are lacking [11]. This site reads the record as it stands — what is genuinely shown, what is rodent-only, and where the human data stop — and keeps the regulatory picture, including the [FDA 503A compounding category](/legal-status), clearly flagged. Nothing here is for sale and nothing here is medical advice.

## What BPC-157 Is Studied For

The BPC-157 benefits people search for map onto a research record, not a clinical indication — there is no approved use anywhere. In animal models the peptide has been studied across tissue types. A fully transected rat Achilles tendon healed faster across biomechanical, functional, microscopic and macroscopic measures after once-daily intraperitoneal dosing, and tendocyte outgrowth increased in vitro [1]. Gastric-ulcer area shrank, with an ulcer-formation inhibition ratio of `45.7-65.6%` at the higher doses tested in rats [4]. In a rat acute-pancreatitis model the peptide reduced distant-organ damage in liver, kidney and lung [13].

Human signals are limited and uncontrolled. A knee-pain case series reported reduced pain across several pain types after intra-articular injection, with no comparator group [6]. A 12-patient intravesical pilot in interstitial cystitis reported symptom resolution in most patients after a single dose during cystoscopy [14]. These are early signals, not efficacy verdicts. The [human pilot studies](/research) are the next chapter, not the conclusion of the first.

## BPC-157 as a Gastric Pentadecapeptide

BPC-157 is, literally, a pentadecapeptide — a chain of fifteen amino acids. The BPC-157 peptide is the synthetic stable fragment derived from Body Protection Compound, a protein isolated from human gastric juice; the full source name is Body Protection Compound 157. The descriptor that recurs through the literature is "stable gastric pentadecapeptide," used because the molecule is reported to resist degradation in gastric juice [4].

That gastric stability is the reason oral and peroral routes are of research interest, and it is also why the peptide carries several development designations — `PL 14736`, `PLD-116`, `PL-10` — under which it once entered early inflammatory-bowel-disease trials. None of that makes it an approved drug. It remains a research peptide with an extensive animal record and a very thin human one.

## Read the record by stratum

This field station stratifies a dense literature into layers. The canopy holds the established preclinical findings — angiogenesis, tendon and gut repair, organ protection. The understory holds the mechanism: VEGFR2 up-regulation and internalization, downstream Akt and endothelial nitric-oxide synthase, the FAK-paxillin migration pathway, growth-hormone-receptor sensitization in tendon fibroblasts [3].

The forest floor holds the honest gaps, surfaced rather than buried: validated human pharmacokinetics — none; large controlled human trials — none; long-term human safety data — none. The composed lens of this readout is systemic toxicity-counteraction, the [BPC-157 cytoprotection](/cytoprotection) story of an organism protecting its own tissue. For how doses are expressed in the studies, see the [research dosing context](/dosage). For the regulatory and access picture, see the [BPC-157 legal status](/legal-status) page.

---

A bioluminescent field-station readout of the BPC-157 literature — every figure logged to its source, no clinic in the canopy and nothing here for sale.